Litigation Details for Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. (D. Del. 2024)

Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. (D. Del. 2024)

Docket		Date Filed	2024-07-12
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	None	Referred To
Parties	MSN LABORATORIES PRIVATE LIMITED
Patents	10,071,977; 10,179,119; 10,610,510; 10,980,770; 11,266,622; 11,285,129; 11,566,011; 11,759,446; 11,850,229; 11,918,556
Attorneys	Samoneh Kadivar Schickel
Link to Docket	External link to docket

Details for Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-07-12				External link to document

Litigation summary and analysis for: Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. (D. Del. 2024)

Last updated: June 29, 2026

Vanda v. MSN (1:24-cv-00815): Litigation Summary, Patent Claims, and What the Case Can Mean for Generic Entry

Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. (case no. 1:24-cv-00815) is pending in the U.S. District Court for the District of Delaware. The filing is part of the Hatch-Waxman patent challenge ecosystem and is expected to concern whether MSN’s ANDA can lawfully enter the market for Vanda’s FDA-approved product(s) before the asserted Orange Book patents expire. No dispositive order or final judgment is reflected in the provided record, so only the procedural posture and litigating framework can be stated from the docket identifier alone.

What is the Vanda Pharmaceuticals v. MSN Pharmaceuticals 1:24-cv-00815 lawsuit about?

Direct answer: The suit is a patent litigation matter tied to Vanda’s FDA-listed reference drug and MSN’s attempted regulatory path to market under the ANDA (Hatch-Waxman), with Vanda asserting infringement of one or more listed patents against MSN.

What typically triggers 1:24-cv-00815 Hatch-Waxman litigation

In the Vanda v. generic-company pattern, the reference listed drug patent estate is enforced through one of these mechanisms:

• Paragraph IV: The ANDA filer claims non-infringement, invalidity, or non-enforceability of one or more Orange Book-listed patents.
• Other infringement theories: Sometimes additional patents are asserted based on combination coverage, method-of-use, or formulation claims tied to the ANDA product label and manufacturing approach.

Because the question targets a single, specific docket number, an accurate “about” summary requires the complaint and the asserted patent list. Those filings are not present in the provided information, so a more granular summary cannot be produced.

Which patents are asserted in Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. (1:24-cv-00815)?

Direct answer: The asserted Orange Book patents cannot be identified from the docket identifier alone.

What the asserted-patent list usually includes

In Vanda’s typical portfolio, asserted patents often fall into categories that courts analyze under distinct claim construction and infringement frameworks:

• Method-of-use patents tied to dosing regimens or indications
• Formulation and composition-of-matter patents covering the drug product structure
• Manufacturing-process patents tied to critical process parameters or product attributes
• Device or delivery system patents if the ANDA product design maps to those claims

Without the complaint’s patent numbers and claims, the case cannot be mapped to specific legal issues.

What is the Orange Book status of Vanda’s drug in the MSN dispute?

Direct answer: Orange Book status for the specific asserted patents cannot be determined from the provided information.

How Orange Book status drives the litigation timetable

Hatch-Waxman enforcement generally tracks:

• Patent expiration dates for the listed patents
• Regulatory exclusivity (if applicable) that can operate independently of patents
• 30-month stay mechanics triggered by a Paragraph IV notice and litigation filing timing

The exact patents, their status (listed, expired, delisted), and the triggering notice date are docket-specific and not included in the provided record.

When does the asserted patent estate expire and can MSN launch before that date?

Direct answer: No expiration dates can be stated without the asserted patent numbers.

Timelines Hatch-Waxman litigations usually follow

Courts and ANDA applicants operate against a few standardized clocks:

• 30-month stay from the ANDA submission date or the required triggering event date
• Patent expiration (utility and non-expiring components)
• Exclusivity cliffs (if present)
• Filing and scheduling milestones for claim construction, summary judgment, and trial

The docket-specific timeline cannot be reconstructed without the complaint, the stipulated schedule, and any orders.

What generic entry risks does MSN face if Vanda wins or loses (1:24-cv-00815)?

Direct answer: The direction of market risk depends on whether the court enters judgment of infringement/validity for the asserted patents or dismisses the challenge as non-infringing/invalid.

Risk scenarios

• If Vanda prevails: MSN’s launch is blocked until the asserted patents expire or are otherwise removed from infringement/validity.
• If MSN prevails: MSN can typically proceed to launch once other regulatory and legal prerequisites are satisfied.
• If the case settles: Parties often enter a license or “carve-out” arrangement that sets launch timing or design-arounds.

The provided information does not include the outcome posture (e.g., status of claim construction, summary judgment motions) or any settlement.

Is this case a Paragraph IV challenge, and what is the relevance to the FDA 30-month stay?

Direct answer: The Paragraph IV structure cannot be confirmed from the docket identifier alone.

Why Paragraph IV classification matters

If the case is Paragraph IV-based, it typically indicates:

• Notice of certification under 21 U.S.C. § 355(j)(2)(A)(vii)
• A potential statutory stay of approval for up to 30 months
• Litigation on infringement and validity of specific Orange Book patents

Those specifics require the certification and complaint details.

What motions, hearings, or claim construction steps are in the docket?

Direct answer: The procedural record (e.g., motion to dismiss, claim construction schedule, summary judgment) cannot be listed without access to docket entries beyond the case number.

Standard motion set in Hatch-Waxman patent suits

When available, the docket commonly includes:

• Motions to dismiss for pleading insufficiency
• Markman-related submissions and claim construction hearing
• Daubert motions for expert reliability
• Summary judgment on non-infringement or invalidity
• Trial date scheduling or stay orders pending appeal

No such entries are included in the provided material.

How strong is Vanda’s patent estate in this specific dispute?

Direct answer: Patent strength cannot be evaluated without the asserted claims, the patent prosecution history, and the court’s substantive rulings, if any.

Framework used by courts to evaluate claim strength

Patent “strength” in litigation normally depends on:

• Anticipation and obviousness exposure from the prior art record
• Claim construction outcomes (scope narrowing or broadening)
• Secondary considerations, written description, enablement, and indefiniteness challenges
• Alignment between the ANDA product label and the asserted method claims

Those elements require specific patents and claim language.

What is the remedy posture if Vanda prevails (injunction, damages, licensing)?

Direct answer: The remedy posture cannot be stated from the case number alone.

Common Hatch-Waxman remedies

Depending on the claim category and statutory posture:

• Permanent injunction against FDA approval for infringing products until expiration
• Declaratory judgment on patent validity/infringement
• Damages if infringement is adjudicated and entry occurred during the period at issue

No infringement finding or damages posture is provided.

Has Vanda and MSN Pharmaceuticals entered a settlement or licensing agreement?

Direct answer: Settlement terms cannot be identified from the provided record.

How settlements typically appear in Hatch-Waxman dockets

When present, they usually resolve:

• Launch date or design-around constraints
• License scope and royalty structure
• Dismissal with prejudice and mutual releases
• Confidential terms with publicly docketed order references

No such document is included in the provided information.

What is the impact on investors and commercial planning for Vanda (revenue exposure and launch protection)?

Direct answer: Revenue exposure cannot be quantified without knowing:

• The reference drug’s sales concentration
• The likely design-around scope of MSN’s ANDA
• The asserted patent expiration horizon and litigation stage

What investors typically map from this case

Business planning usually requires:

• Expected damages exposure window
• Risk-adjusted probability of generic entry before expiration
• Expected time to final judgment and appeal timeline

The necessary factual anchors are not present.

How does Vanda v. MSN compare with other Vanda generic patent challenges?

Direct answer: A meaningful comparison is not possible without asserted-patent numbers and the drug product(s) involved.

Comparison dimensions used in real-world analysis

• Similarity of asserted patents (same family members vs different estates)
• Court rulings and claim construction patterns
• Settlements vs adverse judgments in comparable cases
• Product-design constraints affecting infringement

No case-specific details are provided.

Key Takeaways

• Case identified: Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc., docket 1:24-cv-00815, pending in the U.S. District Court for the District of Delaware.
• What is known from the provided record: Only the existence of litigation can be asserted based on the case identifier.
• What cannot be stated accurately: asserted patent numbers, Orange Book status, exclusivity and expiration dates, claim categories, procedural milestones, and any settlement terms.

FAQs

1. What court is handling Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. (1:24-cv-00815)?
   U.S. District Court for the District of Delaware.

2. What is the typical legal basis for Vanda suing an ANDA filer?
   Patent infringement of FDA-listed Orange Book patents associated with the reference drug.

3. Does a pending Hatch-Waxman case automatically block FDA approval?
   Often it triggers statutory stay mechanics, but the stay and its duration depend on the specific certification and litigation timing.

4. What determines whether a generic can launch during an appeal?
   Whether an injunction applies, whether the stay is in effect, and the status of the appellate decision relative to patent expiration.

5. How can investors assess this case without the patent list?
   They generally cannot quantify risk without asserted patents, expiration horizons, and litigation stage, which drive probability-weighted generic entry timing.

References

1. U.S. District Court for the District of Delaware. Case no. 1:24-cv-00815, Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. (docket identifier provided).